Dr. Kanwal P. Raghav
Claim this profileM D Anderson Cancer Center
Studies Colorectal Cancer
Studies Colon Cancer
10 reported clinical trials
21 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
HER2 positive
2Colon Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Kanwal P. Raghav is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Chemotherapy + Immunotherapy
for Mesothelioma
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Recruiting1 award Phase 236 criteria
More about Kanwal P. Raghav
Clinical Trial Related6 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Kanwal P. Raghav has experience with
- Bevacizumab
- Atezolizumab
- Regorafenib
- Trastuzumab
- Cetuximab
- Ceralasertib
Breakdown of trials Kanwal P. Raghav has run
Colorectal Cancer
Colon Cancer
Pancreatic Cancer
Malignant Mesothelioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kanwal P. Raghav specialize in?
Kanwal P. Raghav focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kanwal P. Raghav currently recruiting for clinical trials?
Yes, Kanwal P. Raghav is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Kanwal P. Raghav has studied deeply?
Yes, Kanwal P. Raghav has studied treatments such as Bevacizumab, Atezolizumab, Regorafenib.
What is the best way to schedule an appointment with Kanwal P. Raghav?
Apply for one of the trials that Kanwal P. Raghav is conducting.
What is the office address of Kanwal P. Raghav?
The office of Kanwal P. Raghav is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.